Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

May 7, 2008

Hedgehog pathwa drugs and chemotherapy

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Donald Fleming, MD 
Division Head of Hematology and Oncology, Davis Health System, Inc.
Implications: Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE

Analysis:  The introduction of a new agent to cancer therapy is always interesting. It remains to be seen how the drug interacts with conventional chemotherapy. In some cases it orks and in others it doesn't and may even have disadvantages over chemotherapy without the new drug. It is difficult to predict how these things will turn out and this has been demonstrted tim and time again when one uses the basis for their project"if one drug works good, more will work better". the hedghog path is a tumor repir and growth pathway, but one can see how inhibiting this process can either be good or bad. The only outcome that will be a success is of course a significant improvemnt and with a disease like colorectal cancer PFS may not be enough , as there areso may regimens being developed to salvage patients.

Other Analyses of the Same Source Article:
Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer
May 6, 2008, Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Report a Concern

GLG News: What Experts Think Is Important





Analytics